#Denmark #Scantox #EJBY #DuplexSeq #LatchBio

Scantox Enhances Bioinformatics with DuplexSeq™ Cloud-Based Mutagenesis App

In a significant advancement for bioinformatics, the Scantox Group has recently unveiled its latest innovation: the Scantox DuplexSeq Mutagenesis App. This revolutionary application is hosted on an updated bioinformatics platform and marks a pivotal step in enabling more efficient and accurate mutagenesis assessment for its customers.

Introduction to DuplexSeq™ Technology

The DuplexSeq technology, known for its error-corrected sequencing capability, is now transitioning to a cloud-based platform that aims to enhance its usability and accessibility. Dr. Matt Tate, the Chief Business Development Officer at Scantox, expressed the importance of this upgrade, stating that the DuplexSeq platform is now equipped to cater to the increasing demand for precision in genomic safety evaluations.

Key Features of the Mutagenesis App

The newly launched mutagenesis app provides significant enhancements for Scantox's DuplexSeq assay kits and services. One of its standout features is the ease with which users can execute validated mutation analysis workflows—only a single click is necessary. Moreover, the app includes centralized project and data management tools, allowing for better data visualization, precise reporting tailored to client needs, and easy uploading of historical study data by existing customers.

LatchBio, the platform utilized for this upgrade, was chosen due to its user-friendly interface and its compliance structure designed for regulated non-clinical research. According to Kyle Giffin, the Chief Operating Officer of LatchBio, this platform meets critical standards of data integrity, traceability, and audit readiness, essential for clients operating in highly regulated environments.

Migration and Validation

Clint Valentine, vice president of operations at Fulcrum Genomics and the original architect of the DuplexSeq pipeline, played a pivotal role in this smooth migration to the LatchBio infrastructure. The verification against the original validation dataset from TwinStrand confirmed that the new platform produces equivalent results while maintaining the scientific integrity of the previous versions.

Valentine emphasized the strength and robustness of the originally designed DuplexSeq pipeline, reinforcing user trust in the updated app. The commitment to scientific rigor has been maintained while allowing for superior infrastructure to optimize user experience and application performance.

Availability of Reagent Kits

With the recent advancements, DuplexSeq reagent kits are now readily available, with plans for expanded commercial availability set for the third quarter of 2026. Scantox is committed to supporting the transition by holding a live webinar aimed at onboarding users to the new platform. Interested participants can register via the provided link in their announcements.

About Scantox

Scantox is a preclinical contract research organization (CRO) that specializes in supporting sponsors from compound discovery all the way through to IND-enabling nonclinical development. With operations in Denmark, Sweden, Austria, and the United Kingdom, Scantox is dedicated to delivering high-quality, regulatory-compliant data across various disciplines in drug development. Its expertise stretches widely across central nervous system pharmacology and toxicology studies, including unique big blue® assays in genetically engineered rodents and the advanced DuplexSeq mutagenesis testing.

Founded in 1977 and currently owned by Impilo, a leading Nordic healthcare investment firm, Scantox continues to set the industry standard for reliability and innovation in the laboratory.

Conclusion

As Scantox strides into the future with its DuplexSeq Mutagenesis App, the integration of cloud capabilities and enhanced user features promises to revolutionize the landscape of nonclinical mutagenicity assessment. With the aim of fostering scientific innovation and integrity, Scantox remains at the forefront as a trusted partner in preclinical research.